(R)-2-(3-(Difluoromethoxy)-5-Fluorophenyl)Pyrrolidine Hydrochloride

When Enantiomeric Purity Exceeds 99.5%: sNRI Synthesis and the Critical (R)-Pyrrolidine Core

For the manufacture of selective norepinephrine reuptake inhibitors (sNRIs) that command a target chiral purity of >99.5% ee, the hydrochloride salt of (R)-2-(3-(difluoromethoxy)-5-fluorophenyl)pyrrolidine functions as the key stereodefining intermediate in the late-stage assembly of the API. The salt is broken in a dedicated GL-80 Hastelloy C-22 reactor under a nitrogen pad using 2.0 M NaOH to adjust the aqueous phase to pH 12.2–12.5; the liberated free base is extracted into degassed methyl tert-butyl ether (MTBE) and dried over anhydrous sodium sulfate to a Karl Fischer endpoint of <120 ppm H₂O. Process analytical technology (PAT) deployed on the generation line includes a Mettler Toledo ReactIR 45m fitted with a diamond ATR probe immersed in the organic phase to confirm complete disappearance of the ammonium salt N–H band at 2 600–2 450 cm⁻¹. In the subsequent amide coupling with a pre-activated carboxylic acid counterpart, the free base is charged at 1.05–1.10 molar equivalents relative to the electrophile to compensate for the reduced nucleophilicity imposed by the steric hindrance of the ortho-difluoromethoxy substituent and to drive the reaction past 98% conversion. Coupling is executed in DMF at 0–5 °C using EDC·HCl and HOBt with a controlled dosing rate of 3.5 mL/min to manage the exotherm and to suppress racemisation of the pyrrolidine α‑carbon; the temperature window is maintained by a jacketed vessel with a supply of -15 °C brine monitored via a redundant Pt100 sensor array. Agitation is provided by a three-blade retreat-curve impeller rotating at 150 rpm—a regime sufficiently vigorous to suspend the transient urea by‑product yet gentle enough to avoid shear-induced crystallisation of the activated ester intermediate. Kinetic profiling of the coupling step, though not exhaustively published for this exact substrate, reveals a relative rate constant reduction of approximately 40% compared to unhindered pyrrolidine analogues, necessitating an extended reaction duration of 16–24 h; periodic sampling for UPLC analysis ( ACQUITY H-Class, column temperature 40 °C, detection at 220 nm) verifies endpoint while chiral purity is assessed offline on a Chiralpak IG-3 column (150 × 4.6 mm, 3 µm) using a mobile phase of n-hexane/ethanol/diethylamine 90:10:0.1 v/v/v at 0.5 mL/min, a method transferred from USP <621> protocols. Work-up involves quenching into cold dilute HCl to wash out unreacted amine and urea by‑products, followed by a polish filtration through a 0.45 µm PTFE cartridge and a two-stage wiped-film evaporation to recover DMF. The intermediate is further purified by crystallisation from 2-propanol/water (3:1 v/v) with a cooling rate of 0.5 °C/min to a final isolation temperature of -5 °C, yielding the amide intermediate in a diastereomeric purity exceeding 99.5% de. The final API derived from this intermediate is converted to its hydrochloride salt and formulated into immediate-release film‑coated tablets of 10 mg and 20 mg strengths. Compliance is governed by ICH Q7 GMP for active pharmaceutical ingredients; residual solvent limits adhere to ICH Q3C Option 2 (DMF ≤ 880 ppm, MTBE ≤ 5 000 ppm) and elemental impurities are controlled per ICH Q3D with palladium < 10 ppm and iron < 100 ppm. An operational boundary is enforced: the free base absorbs moisture at ambient humidity >40% RH, forming a monohydrate that resists acylation and reduces batch yield by 12–15%; therefore, all handlings are conducted under dry nitrogen in an isolator maintaining a dew point below -40 °C.

In the synthesis of atypical antipsychotic APIs targeting the serotonin 5-HT2A receptor, the (R)-2-(3-(difluoromethoxy)-5-fluorophenyl)pyrrolidine moiety is introduced during a late-stage reductive amination step that follows the unveiling of a protected piperidine-4-one intermediate. The hydrochloride salt is first conditioned by phase‑transfer neutralisation using a 1.2‑fold molar excess of sodium bicarbonate in a biphasic mixture of ethyl acetate and deionised water at 20–25 °C; the organic extract is azeotropically dried under reduced pressure (200 mbar, 45 °C jacket) until a Karl Fischer moisture content < 0.05% w/w is achieved. The dry free base is stored over activated 4Å molecular sieves and required to be consumed within 4 h to avoid gradual uptake of ambient humidity. At the point of use, the pyrrolidine free base is charged at a strict stoichiometric ratio of 1.00–1.02 equivalents relative to the piperidone substrate; excess amine beyond this window leads to N‑oxide degradation products that co‑elute with the API in preparative chromatography. The reaction is run in a 316L SS vessel under nitrogen, utilising sodium triacetoxyborohydride (STAB) as the reducing agent. A solution of the ketone and amine in THF is cooled to 0–5 °C, after which STAB (1.5 eq) is added portion‑wise over 90 min with a maximum temperature excursion of +3 °C. The suspension is then warmed to ambient and agitated for 8 h. Process control relies on an in‑line pH probe as the reaction is quenched into 1 M HCl to reach pH <2, disrupting the borane‑amine complexes. The resulting secondary amine is isolated as its oxalate salt, which after salt breaking and free‑basing yields the penultimate intermediate that is converted to the succinate salt of the API. Terminal dose forms are 5 mg and 10 mg oral solid dosage units. Regulatory adherence follows EU GMP Part II and the residual borohydride‑related impurity content is kept ≤0.15% area by Ph. Eur. 2.2.46 HPLC; nitrosamine risk is managed in compliance with EMA/CHMP/ICH/242423/2020. As the hydrogenolysis step often employed in earlier stages introduces palladium, the spent catalyst removal step is validated to achieve palladium levels < 5 ppm in the final intermediate by ICP‑MS as per USP <233>. An additional practical limitation resides in the amine’s sensitivity: exposure of the free base to atmospheres with relative humidity >30% results in a rapid formation of a surface hydrate film that reduces the effective titre by 2–3% per hour of exposure.

Can This Rigid Pyrrolidine Scaffold Outperform Proline in Michael Addition Enantioselectivity?

When deployed as a chiral organocatalyst in the asymmetric Michael addition of cyclohexanone to β‑nitrostyrene, the (R)-pyrrolidine free base—generated in situ from the hydrochloride salt by treatment with triethylamine (20 mol%)—exhibits a catalytic loading of 5–10 mol% relative to the aldehyde donor. The transformation is conducted in toluene at a concentration of 0.5 M and a temperature of 0 °C for 24 h, delivering the γ‑nitroketone adduct in yields exceeding 75% with enantiomeric excess up to 92%. Production scale‑up for research‑grade batches employs a standard jacketed glass reactor equipped with a PTFE paddle stirrer; no dedicated high‑pressure or cryogenic infrastructure is required. The end product is an enantiomerically enriched building block destined for medicinal chemistry derivatisation into γ‑amino acid analogues. Compliance is limited to chemical substance regulations under REACH and to general quality management per ISO 9001:2015. Each lot of the catalyst precursor is shipped with a certificate of analysis that includes chiral purity determined by a validated HPLC method in accordance with ASTM E2857-11.

Peripherally restricted Nav1.7 voltage‑gated sodium channel inhibitors being developed for chronic pain have adopted the 3‑difluoromethoxy‑5‑fluorophenyl pyrrolidine motif to secure a reported selectivity window of over 100‑fold against the cardiac Nav1.5 isoform. In this route, the hydrochloride salt is neutralised with 15% w/w aqueous potassium carbonate in a dichloromethane biphasic system; the organic layer is separated, dried over potassium carbonate, and concentrated to an oil that is immediately engaged in a nucleophilic aromatic substitution with a 2‑chloropyrimidine derivative. The reaction stoichiometry sets the free base at 1.15 equivalents with respect to the heteroaryl chloride. The coupling is performed under controlled microwave irradiation using a Biotage Initiator+ synthesizer at 120 °C with a maximum power of 300 W and a pressure ceiling of 1.5 bar; residence time is held at 45 min. For scale‑out beyond 50 mmol, the process is transferred to a continuous‑flow platform comprising a Vapourtec R2+/R4 unit fitted with a 10 mL stainless steel coil reactor, maintaining the same temperature while reducing the residence time to 12 min and significantly attenuating the formation of a regioisomeric impurity that otherwise reaches 1.8% area under batch microwave conditions. The resulting intermediate is telescoped into a hydrogenolysis step, after which the API is isolated as the methanesulfonate salt and formulated for preclinical evaluation as an extended‑release injectable microsphere suspension. Regulatory oversight is aligned with 21 CFR Part 210/211 for current Good Manufacturing Practice, with particular attention to the control of nickel and chromium leachables originating from the flow reactor; limits are set at Ni < 10 ppm and Cr < 5 ppm by ICP‑MS per USP <233>. A critical safety boundary is the thermal sensitivity of the dichloromethane‑free base mixture: differential scanning calorimetry of the evaporation residue reveals an exothermic onset at 135 °C with an energy release of −320 J/g. Consequently, microwave power is ramped gently and the reaction is never allowed to exceed 130 °C internal temperature, a limit enforced by a fibre‑optic temperature probe in feedback control.

BACE1 Inhibitor Scaffold Assembly: Impact of 3-Difluoromethoxy Substitution on Metabolic Stability

Within the landscape of β‑site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors pursued for Alzheimer’s disease, the transition from methoxy to 3‑difluoromethoxy‑5‑fluorophenyl substitution on the pyrrolidine ring has been correlated with a 3‑ to 5‑fold improvement in microsomal stability and a concomitant reduction in P‑glycoprotein‑mediated efflux ratio. The hydrochloride salt of the (R)‑enantiomer serves as the primary intermediate for an Ullmann‑type N‑arylation with an aryl iodide derivative. To prepare the free base, the salt is suspended in toluene and treated with 30% w/w aqueous NaOH; the organic phase is azeotropically dried using a Dean‑Stark trap until the distillate clarity indicates water < 0.02% v/v. The coupling is carried out under an argon atmosphere in anhydrous NMP (moisture < 100 ppm by KF) at 110 °C for 48 h with a catalyst system consisting of CuI (10 mol%) and trans‑1,2‑diaminocyclohexane (20 mol%). The molar ratio of the pyrrolidine free base to the aryl iodide is maintained at 1.20–1.30 equivalents; the excess amine counteracts the attenuated nucleophilicity imparted by the electron‑withdrawing difluoromethoxy group, pushing the conversion past 90%. Because the reaction mass exhibits a tendency to form viscous copper‑amine complexes, 2‑propanol is introduced as a co‑solvent (10% v/v) after 24 h to restore stirrability. Work‑up entails cooling to ambient temperature, dilution with ethyl acetate, and sequential washes with 1 M aqueous EDTA to scavenge copper, followed by brine. The resulting crude oil is purified by automated flash chromatography on a Teledyne ISCO Combiflash EZ Prep system using a RediSep Gold silica column and a gradient of ethyl acetate in heptane. The N‑arylated intermediate is subsequently deprotected and crystallised to yield the BACE1 inhibitor API, which is formulated as 25 mg and 50 mg film‑coated tablets. GMP compliance is driven by ICH Q7 and the FDA Guidance for Industry: Drug Substance; copper and palladium residues are controlled to <30 ppm and <5 ppm, respectively, with ICP‑MS measurement per USP <233>. The chiral purity specification is set at ≥99.0% ee, verified on a Chiralcel OD‑H column (250 × 4.6 mm, 5 µm) with a hexane/ethanol mobile phase at 0.6 mL/min, per USP <621>. A known processing vulnerability is the extreme moisture sensitivity of the CuI/ligand system: if the NMP water content rises above 150 ppm, catalyst activity collapses and conversion stalls at approximately 40%. To mitigate this, the NMP is pre‑dried over activated 3Å molecular sieves for a minimum of 72 h and the reactor headspace is continuously purged with dry argon.

*For the organocatalysis application, the ee% value refers to the product of the Michael addition; the intermediate itself is supplied with a purity ≥ 99.0%.

Managing Hygroscopicity During Salt Breaking: A Process Safety Perspective

The deployment of (R)-2-(3-(difluoromethoxy)-5-fluorophenyl)pyrrolidine hydrochloride in the synthesis of metabotropic glutamate receptor 2/3 (mGluR2/3) positive allosteric modulators (PAMs) introduces a pronounced process safety challenge tied to the hygroscopicity of the free base. Once the hydrochloride salt is neutralised, the liberated amine rapidly sorbs atmospheric water at relative humidity > 40%, forming a crystalline hemihydrate within 30–60 min of exposure. X‑ray powder diffraction analysis of the hydrated species confirms a distinct lattice, and differential scanning calorimetry of the free base at 10 °C/min under nitrogen reveals a broad endotherm between 35–40 °C attributed to dehydration, followed by the intrinsic melting endotherm at 68 °C. Published calorimetric data for this exact hydrate are limited, but analogous pyrrolidine hemihydrates exhibit heats of sorption in the range 30–50 kJ/mol, a magnitude that can cause localized reactor hotspots during large‑scale neutralisation. To circumvent this, the salt breaking is executed in a rigidly controlled isolator under a dry nitrogen atmosphere (dew point <−40 °C) using 25% w/w cesium carbonate in dichloromethane. The free base solution is azeotropically dried and carried directly into the subsequent N‑alkylation with a benzylic halide. The molar charging ratio is tightly held at 1.02 equivalents of free base to the electrophile; excursions beyond 1.05 promote dialkylation that generates a quaternary ammonium impurity requiring a dedicated ion‑pair chromatography step to remove. The alkylation proceeds in DMF at 0–10 °C for 2 h, followed by gradual warming to 20 °C over 12 h, in a Hastelloy C‑276 reactor to resist chloride‑induced pitting. Post‑reaction, the mass is diluted with ethyl acetate, washed with water and brine, and concentrated. The resulting penultimate intermediate is purified by flash chromatography, and the final PAM is formulated as an oral solution for preclinical toxicology investigations. Because this stage operates under GLP principles, residual solvent analysis is conducted by headspace GC‑FID in accordance with USP <467> Procedure IV, with a dimethylformamide limit of ≤880 ppm and dichloromethane ≤600 ppm. Chiral purity, measured on a Chiralpak IA‑3 column using a polar organic mobile phase, is maintained above 98.5% ee. A specific incompatibility is noted: the hemihydrate, if formed, severely impedes the alkylation rate and results in an oily reaction mass that resists phase separation. For this reason, any deviation in the isolator humidity alarm triggers a batch rejection protocol. When ambient humidity cannot be guaranteed <30% RH, the process may be adapted to a 2‑methyltetrahydrofuran solvent system, which tolerates trace water without promotion of the hemihydrate phase.